Rev 1: September 2018

FSN Ref: Non-conformity No.:285-2020

Date: 11.12.2020

<u>Urgent Field Safety Notice</u> 3459 Pneumococcus CWPS, 10 mg,

Error on label on Product no (REF): 3459 Pneumococcus CWPS, 10 mg, Lot. ZCWPS1-1, expire date 2024.01.09.

For Attention of*: Identify either by name or role who needs to be aware of the hazard and/or take action. If this is multiple recipients then include full list.

Contact details of local representative (name, e-mail, telephone, address etc.)*

This could be a distributor or local branch of the manufacturer. To be added at the appropriate stage in the different local languages

Field Safety Notice (FSN)

Error on label on Product no (REF): 3459 Pneumococcus CWPS, 10 mg, Lot. ZCWPS1-1, expire date. 2024.01.09.

1. Information on Affected Devices*				
1.	1. Device Type(s)*			
	Antigen Product: Pneumococcus CWPS (Cell Wall PolySaccharide)			
1.	Commercial name(s)			
	Pneumococcus CWPS, 10 mg,			
1.	Unique Device Identifier(s) (UDI-DI)			
	GTIN13: 5713106034590			
	GMDN: 64703			
4. Primary clinical purpose of device(s)*				
	The intended use is CWPS and CWPS Multi are intended for preabsorbing human serum			
	samples before quantitation of specific pneumococcal capsular polysaccharide antibodies.			
	CWPS and CWPS Multi may also be used as a coating agent during performance of an ELISA test.			
1.	5. Device Model/Catalogue/part number(s)*			
	REF: 3459			
1.	6. Software version			
	N/A			
1.	7. Affected serial or lot number range			
	ZCWPS1-1			
1.	Associated devices			
	N/A			

2 Reason for Field Safety Notice					
1. Description of the product problem*					
On the correct label the following is printed:					
Pneumococcus CWPS, 10 mg, ŘEF: 3459, Lot: ZCWPS1-1, expire date: 202					
	Product number (REF) is wrong (differs from REF: 3459) on some labels.				
	Lot number ZCWPS1-1 and expire date is correct.				
2.	2. Hazard giving rise to the FSCA*				
	Minor hazard as the product is not affected.				
2.	Probability of problem arising				
	Wrong use of product since the user believe it is a different product				
2.	4. Predicted risk to patient/users				
	No risk to patients/users				
2.	Further information to help characterise the problem				
	N/A				
2.	6. Background on Issue				
	Label Printer error, in a way that the product number (REF) is wrong on some labels of				
	this lot. Lot number and expire date is correct.				
2.	7. Other information relevant to FSCA				
	No FSCA have been issue, this FSN is for information only				

	3. Type of Action to mitigate the risk*				
3.	Action To Be Taken by the User*				
		•		Return Device	☐ Destroy Device
	☐ On-site device modification/inspection				
	☐ Follow patient management recommendations				
	☐ Take note of amendment/reinforcement of Instructions For Use (IFU)				
		□ Other □ None			
2		December about 4 to a	An 2000 00 no	posible and latest	15. February 2021
3.	2.	By when should the action be completed?	As soon as po	ossible and latest	15. Febluary 2021
3.	3.	3. Particular considerations for: N/A			
		Is follow-up of patients or review of patients' previous results recommended? N/A			
		14/7			
3.	4.			es	
		yes, form attached specifyin	,		
3.	5. Action Being Taken by the Manufacturer				
		☑ Decident Decident	7 O	: /:	
			On-site device modificati	ion/inspection	
		· -	IFU or labelling change None		
		□ Otriei	None		
3	6.	By when should the	2021-02-15		
		action be completed?			
3.		Is the FSN required to be communicated to the patient No /lay user?			
3	8. If yes, has manufacturer provided additional information suitable for the patient/lay				
	user in a patient/lay or non-professional user information letter/sheet?			eet?	
		N/A			

FSN Ref: Non-conformity No.:285-2020

	4. General Information*			
4.	1. FSN Type*	New		
4.	For updated FSN, reference number and date of previous FSN	N/A		
4.	3. For Updated FSN, key new information	nation as follows:		
	N/A			
4.	4. Further advice or information already expected in follow-up FSN? *	No		
4	5. If follow-up FSN expected, what is N/A	nat is the further advice expected to relate to:		
4	Anticipated timescale for follow- up FSN	No follow up necessary		
4.	(For contact details of local representative refer to page 1 of this FSN)			
	a. Company Name	SSI Diagnostica A/S		
	b. Address	Herredsvejen 2, 3400 Hillerød, Denmark		
	c. Website address	www.ssidiagnostica.com		
4.	8. The Competent (Regulatory) Authority of your country is been informed about this communication to customers.			
4.	9. List of attachments/appendices:	If extensive consider providing web-link instead.		
4.	10. Name/Signature 2020-12-14	Lotte Lambertsen Cand Scient, Ph.D. Team leader		

Transmission of this Field Safety Notice

This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate)

Please transfer this notice to other organisations on which this action has an impact. (As appropriate)

Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.

Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.

FSN Ref: Non-conformity No.:285-2020

Customer Acknowledgment form

Please read this document in conjunction with Field Safety Notice 3459 Pneumococcus CWPS, 10 mg and return the completed and signed form as soon as possible but no later than 2021.02.15 to SSI Diagnostica A/S By completing the form, you confirm you have destroyed, returned and/or used all vials of the lot covered by the FSN.

Name of Site	
Name of organization covered by this	
response	
Email address	
Telephone Number	
Name	
Signature	
Date	